secwatch / observer
8-K filed April 18, 2025, 7:59 PM ET ticker CTXR CIK 0001506251
other material confidence high sentiment neutral materiality 0.55

Citius issues CEO super-voting stock to push 16M-to-250M share increase; quorum cut to 1/3

Citius Pharmaceuticals, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Citius Pharmaceuticals, Inc.: Filed Certificate of Designation for Series A Preferred Stock with specific voting, redemption, and non-economic terms (effective 2025-04-17).

Change
charter amendment
Effective
2025-04-17
Exact text from the filing
On April 17, 2025, the Company filed a certificate of designation (the “Certificate of Designation”) with the Nevada Secretary of State, effective as of the time of filing, designating the powers, rights, privileges and restrictions of the shares of Series A Preferred Stock.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Citius Pharmaceuticals, Inc.: Reduced quorum requirement for stockholder meetings from majority to at least one-third of voting power (effective 2025-04-16).

Change
bylaw amendment
Effective
2025-04-16
Exact text from the filing
As of April 16, 2025, the Board approved the amendment of the Company’s Amended and Restated Bylaws, effective as of April 16, 2025 (the “Bylaws Amendment”), to reduce the quorum required for the transaction of business at stockholder meetings from the holders of at least a majority of the voting power of the Company’s outstanding shares of capital stock to the holders of at least one-third (1/3) of the voting power of the Company’s outstanding shares of capital stock.
View on SEC.gov

Browse all governance changes →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-25-033366
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.